About
I’m a digital transformation leader passionate about shaping the future of healthcare and…
Articles by Jeordan
Activity
4K followers
-
Jeordan Legon reposted thisJeordan Legon reposted thisHe didn’t just launch a company—he launched an entire industry. One idea, $500, and biotech was born. Bob Swanson (1947-1999, Brooklyn, NY) was an American venture capitalist and a foundational figure in the biotechnology industry. As co-founder of Genentech, the world’s first biotechnology company, he served as CEO from 1976 to 1990 and chairman from 1990 to 1996. Swanson earned a B.S. in Chemistry and an M.S. in Management from MIT in 1970. He began his career at Citibank, managing venture investments and later helping establish Citicorp Venture Capital’s San Francisco office. In 1974, he joined Kleiner & Perkins, where his interest in recombinant DNA technology took shape. After the firm chose to pull back from science-based ventures, Swanson departed but remained committed to pursuing biotechnology. In 1976, he met biochemist Herbert Boyer. Their meeting led to the founding of Genentech, each investing $500. Swanson secured $100,000 in seed funding from Kleiner & Perkins and became president and treasurer. Genentech’s first breakthrough came in 1977 with the successful synthesis of somatostatin using genetically engineered bacteria. In 1978, they synthesized human insulin, leading to a strategic partnership with Eli Lilly. Under Swanson’s leadership, Genentech pioneered genetic engineering, secured key patents, and built a model for industry-academia collaboration. In 1980, Swanson led Genentech through a record-setting IPO, raising $35 million—the largest in biotech history at that time. In 1985, the FDA approved Genentech’s human growth hormone, Protropin, marking a turning point for biotech commercialization. Swanson remained chairman until retiring in 1996. He died in 1999 at age 52 from brain cancer. His legacy lives on through Genentech, which continues to innovate and uphold practices he instituted, such as enabling scientists to publish research. Under his leadership, Genentech developed the first drug via genetic engineering, became the first biotech firm to go public, and was the first to market its own drug—securing Swanson's lasting place in biotech history. 📮Follow Richard Toad for daily profiles of investors and founders
-
Jeordan Legon shared this#TeacherAppreciationWeek Terrific blog post. Both of my parents were teachers and this made me think of them and all of the teachers who supported me. “Appreciation with Identity: Honoring the Teachers Who Help Students Thrive by Being Themselves” https://lnkd.in/eTd-4qBBJeordan Legon shared thisToo many students grow up without ever seeing their culture reflected in the classroom. This Teacher Appreciation Week, our Managing Director of People, Culture & Operations, Charly Schwartz, shares a personal story about identity, representation, and the piano teacher who helped him realize he could bring his whole self to learning. Click the link to read the blog:Appreciation with Identity: Honoring the Teachers Who Help Students Thrive by Being Themselves - Latinos for EducationAppreciation with Identity: Honoring the Teachers Who Help Students Thrive by Being Themselves - Latinos for Education
-
Jeordan Legon reposted thisJeordan Legon reposted thisA world in which we can prevent disease and its progression? Advanced technologies like AI are integral to making this vision a reality. They definitely weren’t on my radar when I started in this industry decades ago – yet they’re now an essential part of what’s ahead (and honestly, what’s upon us). Have a listen! #AheadTogether #AmbitiousForPatients #GSKProud
-
Jeordan Legon shared this#AI Acceleration is on -- even in healthcare. The FDA cleared 223 AI-enabled medical devices last year. Thanks to Larry Mickelberg for posting. #generativeai #agenticaiJeordan Legon shared this🌍 The 2025 Stanford University AI Index is out — and it paints a stunning picture of AI's momentum, impact, and growing complexity. At Axonal.AI, we see these global trends not just as milestones, but as signals—opportunities to drive better, faster, and more ethical innovation in life sciences marketing. 🔬 Here’s what stood out—and how we’re leaning in: AI performance is accelerating. From GPQA to SWE-bench, benchmarks are being shattered. This matters deeply in commercialization, where precision and clarity are non-negotiable. We're engineering agents that don’t just perform well—they understand deeply. AI is everywhere—including healthcare. The FDA cleared 223 AI-enabled medical devices last year. As AI embeds in diagnostics and therapeutics, Axonal is focused on closing the communication gap—helping ensure these breakthroughs reach the right minds, at the right moment, with context and confidence. Business is all in on AI. With $109B in U.S. private AI investment in 2024, the world is betting big. We’re building for this future: helping life sciences teams transform data, insights, and outreach into synchronized, intelligent action. The frontier is tightening. Nearly 90% of top models now come from industry. This raises the stakes—and the bar. At Axonal.AI, we’re not just tracking the frontier. We're applying frontier models (and training our own) to push science-driven marketing forward with speed and integrity. Responsible AI is no longer optional. As AI-related incidents rise, ethical design and transparent reasoning must be built-in from day one. Axonal.AI is committed to explainability, auditability, and trust—because when health is on the line, so is everything. AI is becoming radically more efficient and accessible. The cost to run GPT-3.5-class models has dropped 280xin two years. We're using this trend to democratize advanced AI tools for pharma, biotech, and device marketers—without the enterprise bloat. This report makes one thing clear: AI is no longer emerging. It has emerged. At Axonal.AI, we’re here to ensure that the business gets smarter alongside it. 📚 Read the full Stanford AI Index here: https://lnkd.in/efkNG92s 💡 Learn more about our work: www.axonal.ai
-
Jeordan Legon shared thisTerrific article explaining Agentic Architecture, which enables AI agents to act with a degree of autonomy and make decisions based on goals without the constant need for human input. Exciting times. Thanks to Ken Winell for sharing. https://lnkd.in/eEck_md4
-
Jeordan Legon reposted thisJeordan Legon reposted thisIt’s an exciting time at GSK! Check out this newly created role focused on compliantly enhancing the partnership and role of the Specialty Pharmacy within our patient access journey. This role will be highly collaborative across our Patient Experience operations team, field-based access and reimbursement team, analytics team, and trade and channel teams.
-
Jeordan Legon reposted thisJeordan Legon reposted thisScientists at Harvard Medical School have designed a versatile, ChatGPT-like AI model capable of performing an array of diagnostic tasks across multiple forms of cancers.
Jeordan Legon commented on a post
2w
Congratulations, Sam 🎉 and congrats to Insulet for making a great hire.
Jeordan Legon commented on a post
1mo
Serial entrepreneur indeed! Thanks for all you do for patients and for our industry, John. Corsera Health's vision to end cardiovascular disease is admirable. Enjoyed the interview on BiotechTV: https://www.biotechtv.com/post/corsera-health-john-maraganore
-
Jeordan Legon reacted on thisJeordan Legon reacted on this#Alnylamproud to have volunteered during our annual Community Service Week! This year, I contributed to building 300 STEM education kits for Science from Scientists, an organization committed to educating and inspiring the next generation of scientists and engineers. At Alnylam, we understand the significance of investing in early STEM education to cultivate a future talent pool essential for delivering innovative medicines to patients. Grateful to Science from Scientists for their impactful work!
-
Jeordan Legon reacted on thisI’m beyond proud of the entire team at EVERSANA INTOUCH for earning this recognition. This award is more than a trophy, it’s a reflection of the relentless passion, creativity and purpose-driven work we bring to life every day. In an industry that never stands still, our commitment to innovation, empathy and impact continues to set us apart. We don’t just build campaigns; we build connections that change lives. To our clients: thank you for trusting us to tell your brand stories. To our teams: thank you for pushing boundaries and redefining what’s possible. To the industry and PM360 Magazine: thank you for recognizing the power of what we do together. Congratulations to all! #AgencyOfTheYear #PharmaMarketing #InnovationJeordan Legon reacted on thisWe’re honored to be named the 2025 Agency of the Year by PM360! It’s a true testament of our relentless pursuit to boldly redefine #PharmaMarketing. We took home three awards tonight at the #PM360TrailblazerAwards, celebrating the incredible work of our teams and clients and their commitment to excellence. Congratulations to all, and thank you, PM360 Magazine, for a memorable evening! Learn more: https://ow.ly/zyml50X4Kyt Stay tuned for more details in PM360’s November issue.
-
Jeordan Legon liked thisJeordan Legon liked thisToday we announced that the first patient has been dosed in our Phase 3 Cardiovascular Outcomes Trial (CVOT) evaluating the potential of #RNAi in reducing the risk of major adverse #cardiovascular events in patients with uncontrolled #hypertension. Learn more: https://bit.ly/3VLP4sd
-
Jeordan Legon liked thisJeordan Legon liked thisThis week, 1,000 of our Alnylam colleagues will be rallying together to give back to the communities where we live and work as part of our annual Community Service Week. From Boston to Tokyo, and a dozen countries in between, we’re #Alnylam proud to be supporting 50+ incredible nonprofit organizations that are working every day to build stronger, healthier communities around the globe. #CommunityService #CSR Science Club for Girls
-
Jeordan Legon liked thisGreat role working for a fantastic leader!Jeordan Legon liked thisAre you ready to shape the future of procurement at GSK? At GSK, we unite science, technology, and talent to get ahead of disease together. We are looking for a Procurement Director, North Americas to drive impact, innovation, and value in our Philadelphia, PA or Durham, NC office. I’m #hiring. Know anyone who might be interested?
-
Jeordan Legon liked thisToday is #WorldHeartDay! ❤️ At Alnylam, our commitment to cardiovascular health extends beyond groundbreaking science. We're dedicated to developing innovative therapies for patients where current options are limited, and equally passionate about supporting the patient community every step of the way.Jeordan Legon liked thisToday is #WorldHeartDay! For 25 years, we have come together on 29 September to make heart health a global priority. Right now, people around the world are missing out on time with loved ones, the chance to protect their own health, and the opportunities afforded by more sustainable local health systems. Too often, this is due to the premature and preventable loss caused by cardiovascular disease, the world’s biggest killer. That's why, this year, we tell the world #DontMissABeat: every heartbeat counts, and our mission remains as urgent as ever. Join us: http://worldheartday.org/
-
Jeordan Legon reacted on thisJeordan Legon reacted on thisThis new study highlights the potential of wearable biosensors to transform the management of cystic fibrosis. Researchers validated a soft, skin-mounted microfluidic sweat patch that can measure chloride concentrations outside of specialized laboratories. The patch showed strong correlation with gold-standard chloridometry and demonstrated feasibility for repeated, remote use during exercise. Why does this matter? Sweat chloride is a critical biomarker for monitoring disease progression and treatment response in cystic fibrosis, particularly for patients on CFTR modulators. Traditional methods are invasive, time-consuming and limited to referral centers. A wearable solution could enable more frequent monitoring, provide insights into day-to-day variability and help tailor treatment more precisely. At the same time, caution is needed. The device is not a replacement for gold-standard diagnostic tests and variability in results for people with cystic fibrosis shows that clinical integration will require further validation. Moreover, issues such as patient usability, equity of access and regulatory oversight will determine whether this innovation can scale responsibly. #DigitalHealth #Wearables #Biomarkers #CysticFibrosis #RemoteMonitoring #PatientCentricCare #HealthInnovation #PersonalizedMedicine #mHealth #TranslationalResearch https://lnkd.in/d9EvRtFw
-
Jeordan Legon reacted on thisJeordan Legon reacted on thisImagine a world without cardiovascular disease. On #WorldHeartDay, we’re reminded why accurate, early prediction and effective prevention are at the core of our mission at Corsera Health. Follow along to learn more about how we are redefining the future of cardiovascular health.. ❤️
Experience & Education
-
GSK
View Jeordan’s full experience
See their title, tenure and more.
or
Projects
-
Roche Stories
We're taking stories published on the Roche intranet and getting them approved and published externally on Roche.com. This has helped to increase engagement on our external digital properties and added content we can promote on Roche's social media channels.
Other creators -
-
Integrated AI/ML Algorithms to make Benlysta marketing more effective
-
Increased impact and speed at delivering HCP campaigns by leaning in on Artificial Intelligence and Machine Learning algorithms to determine the next best content to be delivered. This increased engagement and lowered the amount of time to deliver ads and emails by leaning in on tech.
Languages
-
English
Native or bilingual proficiency
-
Spanish
Native or bilingual proficiency
Recommendations received
16 people have recommended Jeordan
Join now to viewOther similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content